SCHEMBL6009423

SCHEMBL6009423

CC(C)(Cc1ccc(F)cc1)NCC(F)(F)CS(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.44
CASR P41180 3/20 0.41
KDM4E B2RXH2 1/20 0.38
DPP8 Q6V1X1 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
HPGD P15428 1/20 0.35
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
MMP2 P08253 1/20 0.33
MMP8 P22894 1/20 0.33
MMP12 P39900 1/20 0.33
ADAMTS5 Q9UNA0 1/20 0.33
GHSR Q92847 1/20 0.32
RIPK1 Q13546 2/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LATS1 O95835 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503937 0.89 HPGD (0.36) DPP4CASRHPGDGHSRCYP3A4
SCHEMBL6009449 0.78 CASR (0.44) DPP4CASRKDM4EDPP8DPP7
SCHEMBL6009982 0.78 DPP4 (0.44) DPP4CASRKDM4EDPP8DPP7
SCHEMBL5518076 0.74 DPP4 (0.45) DPP4CASRKDM4EDPP8DPP7
SCHEMBL5503686 0.74 CASR (0.48) DPP4CASRKDM4EADRB2ADRB1
SCHEMBL5506849 0.67 GHSR (0.39) DPP4CASRHPGDADRB1GHSR
SCHEMBL6009956 0.67 HPGD (0.36) DPP4CASRHPGDADRB1GHSR
SCHEMBL9718295 0.66 KDM4E (0.57) DPP4KDM4EHPGDMMP2MMP8
SCHEMBL8384266 0.66 KDM4E (0.53) DPP4CASRKDM4EHPGDMMP2
SCHEMBL10087249 0.66 LMNA (0.63) DPP4CASRKDM4EHPGDMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR DPP4 1442/4885CASR 3333/4885KDM4E 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.